Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
Authors
Keywords
-
Journal
Clinical Journal of the American Society of Nephrology
Volume Publish Ahead of Print, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-03-17
DOI
10.2215/cjn.0000000000000149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Disease in Chronic Kidney Disease
- (2021) Joachim Jankowski et al. CIRCULATION
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
- (2021) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
- (2021) Panagiotis I. Georgianos et al. Kidney International Reports
- Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
- (2021) Ulrich Kintscher et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Daiji Kawanami et al. Frontiers in Pharmacology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression to Stage 4 chronic kidney disease and death, acute kidney injury and hospitalization risk: a retrospective cohort study
- (2015) Maneesh Sud et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)
- (2014) Lynda A. Szczech et al. PLoS One
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Estimation of treatment effect under non-proportional hazards and conditionally independent censoring
- (2012) Adam P. Boyd et al. STATISTICS IN MEDICINE
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
- (2009) Lisa M. Einhorn et al. ARCHIVES OF INTERNAL MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started